Department of Oral and Maxillofacial Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Department of Radiation Oncology, Kumamoto University Hospital, Kumamoto, Japan.
J Extracell Vesicles. 2021 Dec;10(14):e12169. doi: 10.1002/jev2.12169.
Despite advancements in treatments, oral squamous cell carcinoma (OSCC) has not significantly improved in prognosis or survival rate primarily due to the presence of treatment-resistant OSCC. The intercellular communication between tumour cells is a molecular mechanism involved in acquiring OSCC treatment resistance. Extracellular vesicles (EVs) and encapsulated miRNAs are important mediators of intercellular communication. Here, we focused on EVs released from clinically relevant radioresistant (CRR) OSCC cells. Additionally, we evaluated the correlation between miRNA expression in the serum samples of patients who showed resistance to radiotherapy and in EVs released from CRR OSCC cells. We found that EVs released from CRR OSCC cells conferred radioresistance to radiosensitive OSCC cells via miR-503-3p contained in EVs. This miR-503-3p inhibited BAK and impaired the caspase cascade to suppress radiation-induced apoptosis. Furthermore, OSCC cells with BAK knockdown had increased radioresistance. Additionally, the expression of circulating miR-503-3p in patients with OSCC was correlated with a poor treatment response and prognosis of radiotherapy. Our results provide new insights into the relationship between EVs and the radioresistance of OSCC and suggest that the miR-503-3p-BAK axis may be a therapeutic target and that circulating miR-503-3p is a useful prognostic biomarker in the radiotherapy of OSCC.
尽管在治疗方面取得了进展,但口腔鳞状细胞癌(OSCC)的预后或生存率并没有显著改善,主要是由于存在治疗耐药性 OSCC。肿瘤细胞之间的细胞间通讯是获得 OSCC 治疗耐药性的一种分子机制。细胞外囊泡(EVs)和包裹的 miRNA 是细胞间通讯的重要介质。在这里,我们专注于从临床相关耐辐射(CRR)OSCC 细胞释放的 EVs。此外,我们评估了对放射治疗有耐药性的患者的血清样本中 miRNA 表达与 CRR OSCC 细胞释放的 EVs 之间的相关性。我们发现,CRR OSCC 细胞释放的 EVs 通过其中包含的 miR-503-3p 赋予对放射敏感的 OSCC 细胞放射抗性。这种 miR-503-3p 抑制 BAK 并破坏半胱天冬酶级联反应,从而抑制辐射诱导的细胞凋亡。此外,敲低 BAK 的 OSCC 细胞具有更高的放射抗性。此外,OSCC 患者循环 miR-503-3p 的表达与放射治疗反应不良和预后相关。我们的结果提供了 EVs 与 OSCC 放射抗性之间关系的新见解,并表明 miR-503-3p-BAK 轴可能是一种治疗靶标,而循环 miR-503-3p 是 OSCC 放射治疗中有用的预后生物标志物。